Protalix BioTherapeutics Stock (AMEX: PLX)

Dernières nouvelles pour Protalix BioTherapeutics (AMEX:PLX) Stock

Protalix BioTherapeutics

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics Inc

Piolax Inc

Pluxee NV

PLx Pharma Inc

PLx Pharma Winddown Corp

Plexus Corp

WIIM

Protalix BioTherapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.

<h3>Gainers</h3>
<ul>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock increased by 79.5% to $0.48 during Friday's pre-market session. The company's market cap stands at $3.0 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock increased by 51.0% to $0.83. The market value of their outstanding shares is at $1.9 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) stock increased by 29.85% to $4.35. The company's market cap stands at $296.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares increased by 24.77% to $1.36. The company's market cap stands at $108.9 million. </li>
<li>Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) shares increased by 18.62% to $0.43. The company's market cap stands at $28.6 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) stock rose 16.82% to $0.56. The company's market cap stands at $46.2 million. The company's, Q1 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Jade Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) shares decreased by 44.5% to $5.0 during Friday's pre-market session. The market value of their outstanding shares is at $263.0 million. </li>
<li>Varex Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) shares declined by 42.2% to $5.0. The company's market cap stands at $206.1 million. As per the press release, Q2 earnings came out yesterday. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 41.5% to $0.06. </li>
<li>Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) stock decreased by 35.02% to $2.06. The company's market cap stands at $687.9 million. The company's, Q1 earnings came out yesterday. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares declined by 30.93% to $0.41. The company's market cap stands at $2.7 million. </li>
<li>Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) stock fell 26.65% to $2.12. The market value of their outstanding shares is at $168.5 million. As per the news, the Q1 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACET

CRVS

CTMX

GBIO

IOVA

JBIO

NCNA

PLRZ

SHPH

VREX

WORX

12 Health Care Stocks Moving In Friday's Pre-Market Session

Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $0.03 by 266.67 percent. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $10.11 million which missed the analyst consensus estimate of $21.60 million by 53.18 percent. This is a 169.82 percent increase over sales of $3.75 million the same period last year.

Earnings

Earnings Misses

News

Protalix BioTherapeutics Q1 EPS $(0.05) Misses $0.03 Estimate, Sales $10.11M Miss $21.60M Estimate

<h3>Companies Reporting Before The Bell</h3>
• NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $120.47 million. 
• Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $28.07 million. 
• Gogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGO#NASDAQ">GOGO</a>) is likely to report quarterly earnings at $0.08 per share on revenue of $214.44 million. 
• Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) is estimated to report quarterly earnings at $0.08 per share on revenue of $21.60 million. 
• ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) is projected to report quarterly loss at $0.06 per share on revenue of $180.69 million. 
• TELUS Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIXT#NYSE">TIXT</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $650.27 million. 
• EchoStar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) is projected to report quarterly loss at $0.80 per share on revenue of $3.87 billion. 
• Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) is projected to report quarterly loss at $0.05 per share on revenue of $285.18 million. 
• Essent Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESNT#NYSE">ESNT</a>) is projected to report quarterly earnings at $1.65 per share on revenue of $310.79 million. 
• Veren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRN#NYSE">VRN</a>) is likely to report quarterly earnings at $0.29 per share on revenue of $719.90 million. 
• TXNM Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXNM#NYSE">TXNM</a>) is expected to report quarterly earnings at $0.20 per share on revenue of $432.72 million. 
• Algonquin Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AQN#NYSE">AQN</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $652.63 million. 
• Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) is expected to report quarterly earnings at $0.59 per share on revenue of $261.77 million. 
• Docebo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $57.10 million. 
• American Strategic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYC#NYSE">NYC</a>) is projected to report earnings for its first quarter. 
• Plains All American (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>) is projected to report quarterly earnings at $0.45 per share on revenue of $14.00 billion. 
• Enbridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) is expected to report quarterly earnings at $0.95 per share on revenue of $10.31 billion. 
• Creative Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>) is estimated to report earnings for its first quarter. 
• uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) is estimated to report quarterly loss at $0.96 per share on revenue of $6.10 million. 
• Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) is projected to report earnings for its first quarter. 
• Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) is likely to report quarterly loss at $0.01 per share on revenue of $23.68 million. 
• Ultralife (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULBI#NASDAQ">ULBI</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $54.50 million. 
• TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) is projected to report quarterly loss at $0.06 per share on revenue of $47.69 million. 
• NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) is likely to report quarterly loss at $0.14 per share on revenue of $1.87 million. 
• PAR Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAR#NYSE">PAR</a>) is expected to report quarterly loss at $0.04 per share on revenue of $105.16 million. 
• InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $1.45 million. 
• Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) is projected to report quarterly loss at $0.05 per share on revenue of $29.22 million. 
• Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) is projected to report quarterly loss at $0.52 per share on revenue of $918.50 million. 
• Koppers Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOP#NYSE">KOP</a>) is projected to report quarterly earnings at $0.56 per share on revenue of $488.00 million. 
• Rapid Micro Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) is likely to report quarterly loss at $0.27 per share on revenue of $6.63 million. 
• Associated Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AC#NYSE">AC</a>) is estimated to report quarterly loss at $0.47 per share on revenue of $5.33 billion. 
• Federal Agricultural (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGM#NYSE">AGM</a>) is estimated to report earnings for its first quarter. 
• Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) is estimated to report quarterly loss at $0.90 per share on revenue of $10.73 million. 
• First Trust Switzerland AlphaDEX Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSZ#NASDAQ">FSZ</a>) is projected to report quarterly earnings at $0.25 per share on revenue of $171.64 million. 
• Sylvamo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLVM#NYSE">SLVM</a>) is likely to report quarterly earnings at $0.69 per share on revenue of $817.58 million. 
• Strawberry Fields REIT (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STRW#AMEX">STRW</a>) is projected to report earnings for its first quarter. 
• AMC Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMCX#NASDAQ">AMCX</a>) is estimated to report quarterly earnings at $0.81 per share on revenue of $567.23 million. 
• Alpha Metallurgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) is likely to report quarterly loss at $0.17 per share on revenue of $586.15 million. 
• Construction Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROAD#NASDAQ">ROAD</a>) is likely to report quarterly loss at $0.06 per share on revenue of $559.61 million. 
• Starwood Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STWD#NYSE">STWD</a>) is projected to report quarterly earnings at $0.49 per share on revenue of $468.00 million. 
• BKV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKV#NYSE">BKV</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $208.66 million. 
• 1stdibs.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIBS#NASDAQ">DIBS</a>) is expected to report quarterly loss at $0.13 per share on revenue of $22.28 million. 
• Plains GP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAGP#NASDAQ">PAGP</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $12.97 billion. 
<h3>Companies Reporting After The Bell</h3>
• Motorsport Games (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) is estimated to report earnings for its first quarter. 
• ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) is projected to report earnings for its first quarter. 
• Hawaiian Electric Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) is expected to report earnings for its first quarter. 
• Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) is projected to report earnings for its first quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMCX

ANIK

ANIP

CLMT

CMCT

DCBO

DIBS

EMBC

ESNT

GOGO

INUV

KYMR

LOGC

MSGM

NSPR

OCGN

ORLA

PAGP

QURE

ROAD

RPID

SATS

SLVM

STRW

STWD

TIXT

TXNM

ULBI

WULF

Earnings Scheduled For May 9, 2025

Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) is set to give its latest quarterly earnings report on Friday, 2025-05-09. Here's what investors need to know before the announcement.
Analysts estimate that Protalix BioTherapeutics will report an earnings per share (EPS) of $0.03. 
Anticipation surrounds Protalix BioTherapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
The company's EPS beat by $0.02 in the last quarter, leading to a 4.08% drop in the share price on the following day.
Here's a look at Protalix BioTherapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.07</td>
<td>0.06</td>
<td>0.02</td>
<td>-0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.09</td>
<td>0.03</td>
<td>-0.03</td>
<td>-0.06</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
<td>-12.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746727370_0.png" alt="eps graph" />
<h3>Performance of Protalix BioTherapeutics Shares</h3>
Shares of Protalix BioTherapeutics were trading at $2.84 as of May 07. Over the last 52-week period, shares are up 160.45%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/PLX/earnings">To track all earnings releases for Protalix BioTherapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Uncovering Potential: Protalix BioTherapeutics's Earnings Preview

On Monday, Protalix BioTherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLX#NASDAQ">PLX</a>)&nbsp;reported fiscal 2024 earnings of 4 cents, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 1 cent</a>.
The company recorded 2024 sales of $53.40 million, up 31% year over year, slightly below the consensus of $53.94 million.
The increase resulted primarily from an increase of&nbsp;$11.8 million&nbsp;in sales to Chiesi, an increase of&nbsp;$0.6 million&nbsp;in sales to&nbsp;Brazil, and an increase of&nbsp;$0.1&nbsp;million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44352673/protalix-biotherapeutics-reports-fiscal-year-2024-financial-and-business-results" rel="noreferrer noopener">in sales to Pfizer</a>.
Protalix is a biopharmaceutical company focused on developing and commercializing recombinant therapeutic proteins expressed through its plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration approval of a protein produced through plant cell-based in suspension expression system.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/03/44356786/incytes-new-treatment-for-chronic-skin-disease-shows-promising-results-in-latest-clinical-trials-stock-falls" target="_blank" rel="noreferrer noopener">Incyte&#8217;s New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls</a>
Protalix has licensed to Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix&#8217;s first product manufactured through ProCellEx, excluding in&nbsp;Brazil, where Protalix retains full rights. The FDA and the European Medicines Agency approved Protalix&#8217;s second product, Elfabrio, in&nbsp;May 2023.
&#8220;2024 was a record year in revenues from selling goods for Protalix, as we experienced increases in all three of our revenue streams, Chiesi, Pfizer, and Brazil,&#8221; said Dror Bashan, Protalix&#8217;s <a href="https://www.benzinga.com/pressreleases/25/03/n44352673/protalix-biotherapeutics-reports-fiscal-year-2024-financial-and-business-results" target="_blank" rel="noreferrer noopener">president and CEO</a>.
&#8220;We are pleased with the promising results from our first-in-human study of our gout candidate, PRX-115, in adult volunteers with elevated uric acid levels, and hope to build on this momentum with the goal of initiating a phase II clinical trial in patients with gout during the second half of 2025,&#8221; Bashan said. &#8220;At the same time, we continued to evaluate additional pipeline candidates, including PRX-119, for potential further development.&#8221; 
In&nbsp;September 2024, the company repaid its 7.50% Senior Secured Convertible Promissory Notes. The repayment of the convertible notes at maturity was financed entirely with available cash.
&#8220;Now that our debt is fully repaid and we no longer have outstanding warrants, our balance sheet is stronger and we are well-positioned to continue executing on our strategy through 2025 and beyond,&#8221; Bashan added.
In December, Chiesi and Protalix BioTherapeutics announced that the European Medicines Agency validated the Variation Submission for pegunigalsidase alfa to label a less frequent dosing regimen at a dose of 2 mg/kg body weight administered every four weeks in adult patients with Fabry disease. The currently approved dose of pegunigalsidase alfa is 1 mg/kg administered <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42385554/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-validation-of-variation-submissi" rel="noreferrer noopener">every two weeks</a>.
Price Action: PLX stock is up 17.4% at $2.630 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44353774/eventful-monday-for-astrazeneca-aces-phase-3-hypoparathyroidism-trial-inks-technology-pact-european-approval-for-imfinzi-for-lung-cancer" target="_blank" rel="noreferrer noopener">Eventful Monday For AstraZeneca &#8211; What&#8217;s Going On?</a></li>
</ul>
Photo: Shutterstock

Health Care

Trading Ideas

General

Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond

Protalix BioTherapeutics shares are trading higher after the company reported a FY 2024 GAAP EPS beat.

Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.01 by 300 percent. This is a 55.56 percent decrease over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $53.40 million which missed the analyst consensus estimate of $53.94 million by 1.01 percent. This is a 18.47 percent decrease over sales of $65.49 million the same period last year.

Protalix BioTherapeutics FY 2024 GAAP EPS $0.04 Beats $0.01 Estimate, Sales $53.40M Miss $53.94M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Qifu Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) is expected to report quarterly earnings at $1.68 per share on revenue of $597.66 million. 
• LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $23.55 million. 
• NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) is likely to report earnings for its fourth quarter. 
• CBAK Energy Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAT#NASDAQ">CBAT</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $50.11 million. 
• Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $20.21 million. 
• NextPlat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>) is projected to report earnings for its fourth quarter. 
• Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) is projected to report quarterly earnings at $2.07 per share on revenue of $1.81 billion. 
• Inspired Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSE#NASDAQ">INSE</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $81.72 million. 
• Sonida Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDA#NYSE">SNDA</a>) is projected to report earnings for its fourth quarter. 
• Coda Octopus Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODA#NASDAQ">CODA</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $5.74 million. 
• Niu Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) is likely to report earnings for its fourth quarter. 
• Townsquare Media (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSQ#NYSE">TSQ</a>) is expected to report quarterly earnings at $0.58 per share on revenue of $116.41 million. 
<h3>Companies Reporting After The Bell</h3>
• DiaMedica Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMAC#NASDAQ">DMAC</a>) is likely to report earnings for its fourth quarter. 
• Belite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLTE#NASDAQ">BLTE</a>) is expected to report earnings for its fourth quarter. 
• High Tide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) is estimated to report earnings for its first quarter. 
• Eastman Kodak (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KODK#NYSE">KODK</a>) is expected to report earnings for its fourth quarter. 
• Health In Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIT#NASDAQ">HIT</a>) is estimated to report earnings for its first quarter. 
• Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) is likely to report earnings for its fourth quarter. 
• Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $24.03 million. 
• Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) is expected to report quarterly loss at $0.11 per share on revenue of $42.51 million. 
• Natural Gas Services Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGS#NYSE">NGS</a>) is projected to report quarterly earnings at $0.25 per share on revenue of $40.84 million. 
• Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) is projected to report quarterly loss at $0.14 per share on revenue of $3.77 million. 
• FinVolution Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FINV#NYSE">FINV</a>) is likely to report earnings for its fourth quarter. 
• FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) is expected to report quarterly loss at $0.20 per share on revenue of $24.91 million. 
• Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) is likely to report earnings for its fourth quarter. 
• Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) is likely to report quarterly loss at $1.25 per share on revenue of $21.61 million. 
• B. Riley Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) is estimated to report earnings for its fourth quarter. 
• Consolidated Water Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) is likely to report quarterly earnings at $0.28 per share on revenue of $33.60 million. 
• RF Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RFIL#NASDAQ">RFIL</a>) is expected to report earnings for its first quarter. 
• Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $59.09 million. 
• Hallador Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) is likely to report quarterly loss at $0.05 per share on revenue of $102.46 million. 
• Altus Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $46.55 million. 
• Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $244.87 million. 
• Lithium Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAR#NYSE">LAR</a>) is expected to report quarterly loss at $0.04 per share on revenue of $48.40 million. 
• Quanterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) is projected to report quarterly loss at $0.22 per share on revenue of $35.55 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMPS

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLTE

CBAT

CODA

CWCO

DMAC

FGEN

FINV

GETY

HITI

HNRG

HROW

HYPR

INSE

KODK

LNZA

LPRO

NRGV

NRXP

NXPL

QFIN

QTRX

RBOT

RFIL

RILY

SAIC

SGMO

SNDA

Earnings Scheduled For March 17, 2025

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) with a Buy and raises the price target from $10 to $15.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Protalix BioTherapeutics, Raises Price Target to $15

Chiesi Global Rare Diseases, a business unit of the Chiesi and Protalix BioTherapeutics announced that the European Medicines Agency (EMA) has validated the Variation Submission for pegunigalsidase alfa &nbsp;to label a less frequent dosing regimen at a dose of 2 mg/kg body weight administered every four weeks in adult patients with Fabry disease. The currently approved dose of pegunigalsidase alfa is 1 mg/kg administered every two weeks.

Biotech

Chiesi Global Rare Diseases, A Business Unit Of The Chiesi And Protalix Biotherapeutics Announced That The European Medicines Agency Has Validated The Variation Submission For Pegunigalsidase Alfa To Label A Less Frequent Dosing Regimen

Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.06 by 50 percent. The company reported quarterly sales of $17.96 million which beat the analyst consensus estimate of $16.26 million by 10.46 percent. This is a 73.60 percent increase over sales of $10.35 million the same period last year.

Protalix BioTherapeutics Q3 2024 GAAP EPS $0.03 Misses $0.06 Estimate, Sales $17.96M Beat $16.26M Estimate

AFMD

AGAE

AIRI

AKYA

AMAT

AQMS

AREC

ASND

ASTS

AZUL

BENF

BILI

BIOR

BKTI

BKYI

BLUE

BNAI

BNZI

BRAG

BTAI

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNVS

CRIS

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

GLOB

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MUFG

NICE

NOMD

NTES

OCFT

OCUL

OKLO

ONEW

ORGN

PDSB

PHGE

POCI

POST

Earnings Scheduled For November 14, 2024

Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) is gearing up to announce its quarterly earnings on Thursday, 2024-11-14. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Protalix BioTherapeutics will report an earnings per share (EPS) of $0.04.
The announcement from Protalix BioTherapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company missed EPS by $0.05, leading to a 2.15% increase in the share price the following trading session.
Here's a look at Protalix BioTherapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.02</td>
<td>-0.02</td>
<td>-0.03</td>
<td>-0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.03</td>
<td>-0.06</td>
<td>-0.07</td>
<td>-0.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>-12.0%</td>
<td>-3.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731517366_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Protalix BioTherapeutics were trading at $1.32 as of November 12. Over the last 52-week period, shares are down 9.71%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/PLX/earnings">To track all earnings releases for Protalix BioTherapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Protalix BioTherapeutics

Protalix BioTherapeutics To Present Data From Phase I Clinical Trial Of PRX-115 Recombinant PEGylated Uricase Product Candidate

Protalix BioTherapeutics Announced That It Has Repaid In Full Its 7.50% Senior Secured Convertible Promissory Notes Financed Entirely With Available Cash

Protalix BioTherapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Protalix BioTherapeutics Q2 2024 GAAP EPS $(0.03) Misses $0.02 Estimate, Sales $13.474M Beat $12.500M Estimate

<h3>Gainers</h3>
<ul>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares rose 177.7% to $0.37 during Friday's pre-market session. The company's market cap stands at $11.7 million. </li>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) stock increased by 28.17% to $0.13. The market value of their outstanding shares is at $4.6 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) shares moved upwards by 27.0% to $0.15. The market value of their outstanding shares is at $5.7 million. </li>
<li>ZimVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) shares moved upwards by 23.61% to $20.99. The company's market cap stands at $572.7 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) stock moved upwards by 17.16% to $0.17. The market value of their outstanding shares is at $6.6 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares increased by 15.62% to $27.45. The company's market cap stands at $5.1 billion. The company's, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Reneo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPHM#NASDAQ">RPHM</a>) stock fell 13.8% to $1.43 during Friday's pre-market session. The market value of their outstanding shares is at $47.8 million. </li>
<li>Lucy Scientific Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) shares fell 11.33% to $1.41. The company's market cap stands at $2.4 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares declined by 10.01% to $0.13. The market value of their outstanding shares is at $15.4 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock declined by 9.1% to $1.5. The market value of their outstanding shares is at $1.3 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Dynatronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) shares decreased by 8.43% to $0.4. The company's market cap stands at $2.1 million. </li>
<li>Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) stock declined by 7.7% to $1.08. The company's market cap stands at $79.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Protalix BioTherapeutics

Actualités

Dernières nouvelles pour Protalix BioTherapeutics (AMEX:PLX) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL